Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT01572740

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01572740
Other papers using this trial's data
  • Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial Journal of diabetes investigation, 2016-07 DOI, PubMed 27182042, PMC4931207 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial Journal of diabetes investigation, 2018-07 DOI, PubMed 29277968, PMC6031509 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01572740. Randomized; double masking; primary purpose treatment. Start 2012-04-05 (actual); primary completion 2012-11-01 (actual). Results posted on 2014-05-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
placebo
Intervention (Drug)
insulin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01572740
Content hash
8d38269ca423a43cf97a1a3ca78965a432c3dbc90628fd7d28b5fd4cc647c610